<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01847365</url>
  </required_header>
  <id_info>
    <org_study_id>TESOLAUK13</org_study_id>
    <nct_id>NCT01847365</nct_id>
  </id_info>
  <brief_title>TES for the Treatment of RP</brief_title>
  <acronym>TESOLAUK</acronym>
  <official_title>Transcorneal Electrical Stimulation for the Treatment of Retinitis Pigmentosa - a Multicentre Safety Study of the Okustim® System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oxford University Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Moorfields Eye Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retinitis pigmentosa (RP) is a progressive degenerative disease of the retina, which often&#xD;
      leads to blindness. 1 in 4000 people in the UK are affected by RP yet there is no established&#xD;
      therapy for treating or delaying its progression.&#xD;
&#xD;
      Transcorneal electrical stimulation (TES) has garnered attention as a possible therapeutic&#xD;
      option for RP. Research has shown that TES improves retinal cell viability and visual&#xD;
      function. An initial pilot study of TES on 24 participants with RP demonstrated that it was&#xD;
      safe and improved vision.&#xD;
&#xD;
      This study aims to confirm the safety of the new CE-approved Okustim device and to further&#xD;
      characterise the benefits of TES on a larger scale. 12 participants will be enrolled for 1&#xD;
      year across two sites in the UK - the Oxford Eye Hospital and London Moorfields Eye Hospital.&#xD;
&#xD;
      Recruited participants will undergo weekly TES of 1 eye for 30 minutes for a period of 6&#xD;
      months. This will be followed by a further 6 months of observation without stimulation giving&#xD;
      a total participation time of 1 year. Participants will be assessed at 3, 6, 9 and 12 months&#xD;
      after their initial baseline visit by clinical examination, investigations and&#xD;
      questionnaires.&#xD;
&#xD;
      Participants should have a diagnosis of RP and be capable of giving consent. Participants, or&#xD;
      a carer, should have sufficient motor skills to attach the device themselves. As this study&#xD;
      seeks to ascertain the impact of TES on RP, participants with other eye diseases (e.g.&#xD;
      diabetic retinopathy) cannot be included in the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Quantity and Character of Adverse Events Related to the Use of the Device</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Intervention</measure>
    <time_frame>12 months</time_frame>
    <description>Ophthalmic examination, best corrected visual acuity, visual field assessment, microperimetry, optical coherence tomography, fundus photography</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Usability of the Device</measure>
    <time_frame>12 months</time_frame>
    <description>Non-validated questionnaires</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <arm_group>
    <arm_group_label>Retinitis Pigmentosa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcorneal electrical stimulation (TES) administered to one eye for 6 months, followed by monitoring period without treatment for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcorneal electrical stimulation</intervention_name>
    <description>Transcorneal electrical stimulation will be delivered by the CE-marked Okustim device.</description>
    <arm_group_label>Retinitis Pigmentosa</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant is willing and able to give informed consent for participation in the&#xD;
             study&#xD;
&#xD;
          -  Male or Female, 18 or more years of age&#xD;
&#xD;
          -  Diagnosis of retinitis pigmentosa (rod-cone dystrophy) made by an ophthalmologist&#xD;
&#xD;
          -  Participants should have a visual acuity of ≥ 0.02 (Snellen Chart)&#xD;
&#xD;
          -  Able (in the investigators opinion) and willing to comply with all study requirements&#xD;
&#xD;
          -  Willing to allow his or her General Practitioner and consultant, if appropriate, to be&#xD;
             notified of participation in the study&#xD;
&#xD;
          -  Participants, or a designated other, should have sufficient motor skills (assessed by&#xD;
             the investigator) to apply the device independently&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female participants who are pregnant, lactating or planning pregnancy during the&#xD;
             course of the study&#xD;
&#xD;
          -  Diabetic Retinopathy&#xD;
&#xD;
          -  Previous arterial or venous occlusion of the retina&#xD;
&#xD;
          -  Previous retinal detachment&#xD;
&#xD;
          -  Previous silicone oil tamponade&#xD;
&#xD;
          -  Dry or exudative age-related macular degeneration&#xD;
&#xD;
          -  Macular oedema&#xD;
&#xD;
          -  All forms of glaucoma&#xD;
&#xD;
          -  Any form of corneal degeneration that reduces visual acuity&#xD;
&#xD;
          -  Neovascularisation of any origin&#xD;
&#xD;
          -  Any other significant disease or disorder which, in the opinion of the Investigator,&#xD;
             may either put the participants at risk because of participation in the study, or may&#xD;
             influence the result of the study, or the participant's ability to participate in the&#xD;
             study&#xD;
&#xD;
          -  Forms of mental illness related to bipolar affective and schizoid-affective disorders,&#xD;
             and all forms of dementia&#xD;
&#xD;
          -  Simultaneous participation in another interventional study or history of interventions&#xD;
             where effects may still persist&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert E MacLaren, FRCOphth DPhil</last_name>
    <role>Study Chair</role>
    <affiliation>University of Oxford, Oxford University Hospitals NHS Trust and Moorfields Eye Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Susan M Downes, FRCOphth MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oxford University Hospitals NHS Trust and University of Oxford</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew R Webster, FRCOphth MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCL Institute of Ophthalmology and Moorfields Eye Hospital NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.eye.ox.ac.uk</url>
    <description>Oxford Eye Hospital</description>
  </link>
  <reference>
    <citation>Jolly JK, Wagner SK, Moules J, Gekeler F, Webster AR, Downes SM, MacLaren RE. A Novel Method for Quantitative Serial Autofluorescence Analysis in Retinitis Pigmentosa Using Image Characteristics. Transl Vis Sci Technol. 2016 Dec 1;5(6):10. eCollection 2016 Dec.</citation>
    <PMID>27933220</PMID>
  </reference>
  <results_reference>
    <citation>Wagner SK, Jolly JK, Pefkianaki M, Gekeler F, Webster AR, Downes SM, Maclaren RE. Transcorneal electrical stimulation for the treatment of retinitis pigmentosa: results from the TESOLAUK trial. BMJ Open Ophthalmol. 2017 Dec 14;2(1):e000096. doi: 10.1136/bmjophth-2017-000096. eCollection 2017.</citation>
    <PMID>29354722</PMID>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>May 1, 2013</study_first_submitted>
  <study_first_submitted_qc>May 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2013</study_first_posted>
  <last_update_submitted>November 8, 2018</last_update_submitted>
  <last_update_submitted_qc>November 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Retinitis Pigmentosa</keyword>
  <keyword>Transcorneal electrical stimulation</keyword>
  <keyword>Okustim</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

